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Abstract
Dengvaxia was used in the Philippines to vaccinateBackground: 
9-10-year-old school children, living in areas highly endemic for dengue.
After about 830,000 had received at least 1 of 3 recommended doses, risks
of enhanced disease in dengue-naïve vaccinees were reported.
We used Phase 3 trial data to derive the proportions of cases ofMethods: 
hospitalised and severe dengue that might have been prevented by the
Philippines vaccination programme and, among those cases that may
occur in vaccinees, what proportions are likely to arise in those who were
seropositive or seronegative for dengue at the time of first vaccination and
what proportion in the latter group may be enhanced disease attributable to
the vaccine.
 Assuming about 15% of vaccinees were dengue naïve atResults:
vaccination and the effects of the vaccine are independent of the number of
doses received, we estimate that, in the 5 years following vaccination, the
number of cases of severe disease in the vaccinated population will be
reduced by about 70%. Among vaccinees who do develop severe disease,
about half the cases will be due to vaccine breakthrough in seropositive
vaccinees, and about a quarter will be excess cases in seronegative
vaccinees that will have occurred as a consequence of vaccination.
Overall, the Philippine dengue vaccination programme willConclusions: 
likely prevent a substantial number of severe dengue cases and, among
those that do occur, the majority are likely to be breakthrough disease in
seropositive vaccinees and a minority attributable to the excess risk of
enhanced disease in seronegative vaccinees.
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Introduction
Dengue is the most frequent mosquito-borne viral disease, 
with a 30-fold increase in annual reported cases over the past 
50 years and continued geographic expansion1,2, also affect-
ing international travellers3,4. Infection with any of the four 
dengue virus serotypes may be asymptomatic or may result in 
clinical manifestations ranging from relatively mild febrile illness 
to severe dengue manifested by plasma leakage, haemorrhagic 
tendencies, organ failure, shock, and possibly death5. Patients 
with a second dengue infection with a different dengue sero-
type to the first are at a higher risk for severe dengue than from 
the first infection, but subsequent infections with different 
serotypes are not associated with such increased risk5,6.
Dengvaxia, the first licensed dengue vaccine, is a live attenu-
ated vaccine using the yellow fever 17D vaccine virus as its 
backbone. Two Phase 3 efficacy trials of Dengvaxia (then called 
CYD-TDV) were conducted in children aged 2–16 years in 10 
countries in Asia and Latin America at sites in which dengue is 
highly endemic7,8. In the 25 months after the first vaccine dose, 
for those first vaccinated at ages 9 to 16 years, the incidence of 
severe dengue was 93% lower in the vaccinated group than in the 
placebo group and hospitalizations for virologically-confirmed 
dengue (VCD) were reduced by 81%9. However, over the 
first 3 years of follow-up among those first vaccinated at ages 
2–5 years, there was an overall excess of hospitalised dengue 
in the vaccinated group, though this excess risk was not statisti-
cally significant9. At the time of first licensure of Dengvaxia 
in 2015, data from the Phase 3 trials did not allow assessment of 
whether the apparent increased risk of hospitalised and severe 
dengue in those first vaccinated at ages 2–5 years was related 
to age per se, and/or was due to a higher proportion in the younger 
age group being seronegative compared to older children10.
Following licensure for those aged 9 years and above, an 
age group in which no excess risk of hospitalised or severe 
dengue was apparent in the trials, WHO recommended the use 
of the vaccine only in high transmission settings, as defined by 
a seroprevalence of 70% or more, to ensure substantial public 
health impact11 To-date, Dengvaxia has only been used in 
two national immunization programmes, both at sub-national level, 
in the Philippines and Brazil12.
In November 2017, Sanofi Pasteur announced the results of 
further analyses of data from the Phase 3 trials, using a newly 
developed NS1-based ELISA assay that was able to differentiate, 
in large part, between immune responses due to vaccine expo-
sure and those due to natural dengue virus infection. As blood 
samples were taken from only a subset of trial participants prior 
to vaccination, but all participants had a blood sample taken one 
month after the third vaccine dose, the company used the 
results based on blood samples taken post-vaccination to infer 
dengue serostatus before vaccination, for those without a 
baseline sample. These analyses demonstrated that while the 
vaccine offered substantial protection among those who had been 
infected with dengue before vaccination, dengue-naïve vaccinees 
(i.e. seronegative children) were at increased risk for dengue 
hospitalisation and severe dengue during the 5-year trial fol-
low-up compared to unvaccinated seronegative children13. In 
dengue-seronegative participants aged 2–16 years, the hazard 
ratio (HR) for the cumulative 5-year incidence of hospitalization 
for VCD, comparing vaccinated to placebo recipients, was 1.75 
(95% confidence interval [CI], 1.14 to 2.70), and for severe 
dengue the HR was 2.87 (95%CI 1.09-7.61). For those aged 
9–16 years, the corresponding HRs were 1.41 (95% 
CI: 0.74–2.68) and 2.44 (95% CI: 0.47–12.56), respectively. 
In contrast, in seropositive trial participants, the vaccine was 
found to be efficacious and, in those aged 9–16 years, the 
corresponding HRs were 0.21 (95% CI: 0.14–0.31) and 0.16 
(95% CI: 0.07–0.37), respectively13.
Thus, in a vaccinated population consisting of a mixture of 
seronegative and seropositive individuals, cases of hospitalised 
and severe dengue that occur will be composed of breakthrough 
cases among those seropositive at the time of vaccination 
and cases among those seronegative when vaccinated. This 
latter group will be composed of cases that occurred because 
of the failure of the vaccine to protect in this group, that is, the 
number that would have occurred in the absence of vaccina-
tion, and induced cases, because of the enhanced risk due to 
vaccination in this group. The relative proportion of cases 
of breakthrough cases and induced cases of hospitalised and 
severe dengue disease will depend on the seroprevalence 
among those vaccinated.
Dengue is highly endemic in the Philippines and has the high-
est reported number of dengue cases among countries in the 
WHO Western Pacific region. In the first 7 months of 2019, 
there were 130,463 suspected dengue cases reported and 561 
deaths14. Following licensure of Dengvaxia in the Philippines 
in early 2016, there was a vaccination programme in schools 
in selected highly endemic regions, targeting about 1 million 
children aged 9–10 years. The dengue seroprevalence in this 
population is not known, but has been estimated to be between 
80 and 85%, extrapolating from data from the trial sites in the 
Philippines included in the Phase 3 trial15. After Sanofi Pasteur 
reported the safety signal in seronegative vaccinees, in November 
2017, the vaccination programme was suspended. By then, 
over 830,000 children had received the vaccine: about 420,000 
had received 1-dose, 49,000 2-doses and 370,000 3-doses 
(Sanofi Pasteur, personal communication). The suspension of 
the programme broke public trust in the dengue vaccine and 
heightened anxiety around vaccines in general16, and cases of 
hospitalised and severe dengue and deaths due to dengue in 
vaccinated children were widely ascribed, among the public and in 
the media, to being vaccine-induced.
As noted above, the vaccine is only partially effective in serop-
ositive vaccinees, so breakthrough cases would be expected in 
this group, and only in seronegative vaccinees would vaccine-
induced cases be expected. We estimate, for those vaccinated 
with Dengvaxia in the Philippines, the relative proportions of 
hospitalized and severe dengue due to breakthrough disease in 
seropositive vaccinees and due to enhanced disease in seronega-
tive vaccinees, and also estimate the proportion of hospitalized 
and severe cases prevented in seropositive vaccinees, extrap-
olating from the results from the Phase 3 trials of the 
vaccine.
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Methods
Our calculations are based on the retrospective analyses from 
the Phase 3 trials, stratified by serostatus13. We used data 
pooled across all trial sites, which constitute a mixture of 
medium to high dengue burden settings, and only use data 
for children aged 9 years or older. Cumulative incidence esti-
mates for dengue hospitalisations in vaccinees and controls by 
serological status at trial entry, for the 60 months following first 
vaccination, are those based on NS1 test in combination with 
multiple imputation techniques that also account for imper-
fect sensitivity and specificity of the NS1 test. These are taken 
from Table S10 in Sridhar et al.13.
To infer estimates of relative numbers of dengue hospitalisa-
tions and severe dengue episodes in seropositive and seron-
egative vaccinees in the Philippines, we directly extrapolated 
from the trial data13, which includes the estimated seropreva-
lence at trial entry, the annual incidence of dengue infections, 
and the relative risks of hospitalised dengue in vaccinees and 
controls who were seropositive or seronegative at trial entry. In 
brief, similar to the methods in Wilder-Smith et al.10, a vacci-
nated cohort was split into dengue naïve and dengue exposed 
vaccinees and relative incidence estimates from the trial popu-
lation were applied to each of these to obtain estimates of the 
expected relative number of cases among seronegative and sero-
positive vaccinees. We then calculate the proportion among all 
cases that are breakthrough cases among seropositive vaccinees, 
those that occur among seronegative vaccinees and the excess 
cases among those.
Nearly all children in the trials received 3 doses of vaccine, and 
it is not known if the enhanced risk of hospitalised and severe 
dengue in seronegative vaccinees will be the same in children 
who receive only 1 or 2 doses. We assumed that all vaccinees, 
irrespective of the number of doses received, would experi-
ence the same relative risks of hospitalized dengue and severe 
dengue as reported in the trial populations by Sridhar et al.,13 
compared to the situation had they not been vaccinated. Hos-
pitalisation rates for dengue varied substantially between trial 
sites and hence are likely not representative of the Philippines 
setting. Therefore, we do not report absolute incidence 
estimates but restrict ourselves to the reporting of relative meas-
ures which are likely to be largely unaffected by different 
hospitalisation rates. Based on the seroprevalence data from 
the trial sites in the Philippines15 and further seroprevalence 
data in the areas where the vaccine was introduced17, we 
assumed that the seroprevalence among those vaccinated in the 
Philippines was 85%.
The analyses were conducted in R version 3.5.3 and the 
analyses scripts can be found on github: https://github.com/ 
StefanFlasche/Denvaxia-in-Phillippines
Results
In the CYD-TDV Phase 3 trials, the 5-year cumulative inci-
dences of hospitalised and severe dengue in dengue naïve vac-
cine recipients, aged 9–16 years at first vaccination, were 
increased by 44% and 132%, respectively (Sridhar et al, Table 
S1013), compared to those who were seronegative but not 
vaccinated. In seropositive unvaccinated children, the risks of 
hospitalised and severe dengue were 72% and 176% higher, 
respectively, than in seronegative unvaccinated children. In sero-
positive vaccinated children, the incidences of hospitalised and 
severe dengue were reduced by 80% and 84%, respectively, 
in the five years following vaccination compared to those who 
were seropositive but not vaccinated. Assuming 15% of the 
830,000 children vaccinated in the Philippines were seronega-
tive, about 125,000 are at potentially increased risk for hospi-
talised and severe dengue when exposed to their first natural 
infection with wild-type dengue virus following vaccination. 
Assuming that the relative risks in the Philippines are simi-
lar to those observed in the Phase 3 trials, we estimate that, 
over the five years following vaccination in the Philippines, 
Dengvaxia will have averted about 18 dengue hospitalisations 
among seropositive vaccinees for each precipitated dengue 
hospitalisation in dengue-naïve vaccinees, and about 10 
severe dengue cases among seropositive vaccinees for each 
precipitated severe dengue case in dengue-naïve vaccinees.
In the 5 years following vaccination, we estimate that, among 
those dengue cases that are hospitalised in the vaccinated 
Philippine cohort, about 58% will be vaccine breakthrough cases 
in seropositive vaccinees, that result from the high but imper-
fect effectiveness of the vaccine in seropositives (Figure 1). 
We further estimate that of the 42% of hospitalised den-
gue cases that will occur among seronegative vaccinees, 31% 
of these (i.e. 13% of all hospitalised dengue cases) will be 
excess cases that occurred as a consequence of vaccination. 
However, few of those excess cases are likely to occur within 
2.5 years following vaccination as the enhanced dengue risk 
was apparent in the trial population only from about 2 years 
after first vaccination (Figure 1). In the corresponding analysis 
for severe dengue, the estimated proportion of cases due to 
vaccine breakthrough in the 5-years following first vaccination 
is 51%. Of the 49% of severe dengue cases that might be expected 
among seronegative vaccinees, 57% of these (i.e. 28% of all 
severe dengue cases) are excess cases that will have occurred 
as a consequence of vaccination.
We cannot similarly extrapolate the trial findings with respect 
to deaths from dengue, as there were no deaths from dengue 
observed in the Phase 3 trials. However, given the findings 
in the trials that the clinical severity of hospitalised dengue 
in seronegative vaccinees was similar to that in seropositive 
vaccinees, it seems not unreasonable to postulate that the risk of 
fatal outcomes would be similar, in relative terms, to those for 
severe dengue in seronegative and seropositive vaccinees. 
On this basis we speculate that, in the Philippines, in the 
5-years following vaccination, for any death that might have 
occurred in vaccinated seronegatives around 10 deaths would 
be prevented by the vaccination programme in seropositives 
and that among all deaths from dengue in the vaccinated cohort, 
about 28% may be due to an enhanced risk among vaccinated 
seronegatives.
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Discussion
The findings from the Phase 3 trials of CYD-TDV were that, in 
the five years following first vaccination, the vaccine offered 
substantial protection against hospitalised and severe dengue 
among vaccinees who had been previously infected with 
dengue, but that in dengue-naïve vaccinees there was an increased 
risk of these conditions, apparent from about two years after 
the first vaccine dose. Thus, when the vaccine is used in public 
health programmes, the hospitalised and severe dengue cases 
that occur following vaccination will be a mixture of break-
through cases from those who were seropositive when vaccinated 
and cases from those seronegative at vaccination, among whom 
the vaccine offered no protection and increased their likelihood 
of hospitalised and severe disease above the level that would 
have been expected had they not been vaccinated. The relative 
proportions of cases arising through these different mecha-
nisms will depend upon the dengue-seroprevalence among 
those vaccinated. We have tried to estimate these proportions, 
among children who were included in the mass vaccination 
programme with Dengvaxia in the Philippines, based on the 
assumption that about 85% of the children vaccinated would 
have had a previous dengue infection before they were vacci-
nated. The first point to note is that among all those vaccinated, 
the total number of hospitalised and severe dengue cases in 
the five years following vaccination would be expected to be 
reduced by 69% and 71%, respectively, compared to the situa-
tion had no children been vaccinated. Among the cases that would 
be expected to occur in the vaccinated population, we estimate 
that more than 50% of the cases would be in vaccinees who 
were seropositive at the time of vaccination, as a consequence 
of breakthrough disease. Among seronegative vaccinees, a 
sizeable amount of cases of hospitalised and severe dengue also 
would have occurred in the absence of vaccination, but about 
13% of all hospitalised cases and of all 28% of severe cases 
would be excess cases attributable to the enhanced risk 
associated with the vaccination of seronegatives.
It is important to note some of the limitations in our estimates. 
We have extrapolated from the results from the Phase 3 trials 
directly to the public vaccination programme in the Philippines. 
In particular, we have assumed that the relative risks were 
the same for children who were partially vaccinated as for 
those who received all 3 doses. We have no data for partially 
vaccinated children in the Phase 3 trials as all virtually received 3 
doses, and thus do not know if partial vaccination alters the risk 
of enhanced disease in seronegative vaccinees or reduces the 
protective effect in seropositive vaccinees. In the phase 3 trials, 
the overall efficacy between the first and second, and second 
and third vaccine doses were similar and the immunogenicity 
in seropositives was similar after 1, 2 or 3 doses18. The major-
ity of children in the Philippines received only 1-dose and only 
about 44% received all 3 doses. Further, we assume that 85% 
of vaccinees will have been seropositive when vaccinated, 
resulting in an estimated 13% of 5-year cumulative dengue 
hospitalisations in the vaccinated cohort being attributable to 
excess cases among seronegative vaccinees. If, instead, we 
assume that 70% or 90% of vaccinees were seropositive, then, 
the estimated excess cumulative hospitalisations attribut-
able to excess cases among seronegative vaccinees would be 
20% or 10%, respectively, rather than 13%. Other limitations 
include that we do not account for differential vaccine effec-
tiveness by serotype, do not extend our predictions beyond the 
5-year observation period of the trial and do not account for 
more complex immunological dynamics potentially arising 
from differences in population immunity predating vaccina-
tion between the trial population and the vaccinated cohort in 
the Philippines. In addition, media publicity around Dengvaxia 
in the Philippines may have led to milder cases of dengue 
Figure 1. The expected percentage of hospitalised dengue cases in the Philippines vaccinated cohort that might be expected to occur 
in seropositive vaccinees, seronegative vaccinees and the percentage of cases in the latter group that are Dengvaxia attributable.
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among vaccinated children being hospitalised and thus, 
extrapolation based on hospitalised cases in the Phase 3 trials 
may not be valid, though it should be noted that there was sub-
stantial variation between different sites in the Phase 3 trials in 
the proportion of all dengue cases that were hospitalised7,9,19, 
presumably reflecting variation in admission practices for 
dengue.
We also restricted our analyses to inference based on point 
estimates of the relative disease rates in the trials. However, 
uncertainty in all point estimates is substantial. We have 
chosen this approach because the reported confidence inter-
vals on incidence and relative risk in the trials are likely highly 
correlated and hence using the published data it is not possible 
to reflect uncertainty adequately in the analyses.
Perhaps most uncertain are the results we have inferred with 
respect to deaths from dengue. During the clinical trials, 
no deaths from dengue were reported. Outside of the special 
circumstances of a trial, the case fatality ratio of hospitalised 
dengue will likely be higher. Furthermore, we have assumed 
that the findings in the trials with respect to the relative risks 
of severe dengue will approximate those for deaths from 
dengue. We cannot validate this assumption, though to us it 
seems plausible.
Our results cannot be used for causality assessment with 
respect to individual dengue cases. Only a proportion of hos-
pitalised and severe dengue cases occurring in individuals 
without previous dengue infection at the time of vaccina-
tion would be related to an enhanced risk associated with 
vaccination. Clinical management of severe dengue is the same, 
irrespective of baseline serostatus at time of administration of 
Dengvaxia. Testing already vaccinated children with the NS1 
based IgG ELISA would not change clinical management. 
Furthermore, this test has imperfect sensitivity and specificity20. 
Testing all vaccinees to infer retrospectively their serostatus 
at the time of vaccination, using for example the NS1 test, may 
provide false assurance in those estimated to be seropositive at 
the time of vaccination, as they are still at risk of hospitalised 
or severe dengue due to breakthrough disease.
In summary, our calculations may help estimate the respective 
distribution of severe dengue cases among presumably sero-
positive and seronegative individuals following vaccination. 
They indicate that in high transmission settings a majority 
of hospitalised and severe dengue cases among vaccinees are 
expected to come from subjects presumably seropositive at 
time of vaccination. The relative number of cases with break-
through dengue and enhanced dengue will depend on the 
seroprevalence among those vaccinated.
Dengvaxia still has a potential public health role, in the absence 
of currently available alternative solutions, to combat the 
expanding problem of the global dengue burden. The chal-
lenge is how best to use the vaccine balancing the potential for 
public health impact in those previously infected with dengue, 
against the possibility of harm in dengue-naïve vaccinees. 
In communities in which the prevalence of past infection with 
dengue is high in the group targeted for vaccination, and in the 
absence of the application of a specific test to identify previously 
infected persons, the risk of severe dengue will be, on aver-
age, higher in persons not vaccinated than persons vaccinated10. 
The protective effect in the majority who are seropositive 
being greater than the enhancing effect in the minority who are 
seronegative. However, in the latter group some will develop 
severe dengue who would not have developed this in the absence 
of vaccination. This poses substantial communication chal-
lenges for those responsible for vaccination programmes. 
WHO has recommended that for countries considering 
vaccination as part of their dengue control programme, a “pre- 
vaccination screening strategy” is recommended, in which only 
dengue-seropositive persons are vaccinated21. However, this 
strategy also presents major challenges in terms of logistics, 
implementation, communication and additional costs, as 
well as the current absence of a sensitive and specific rapid 
point-of-care test to assess serostatus22.
Data availability
Underlying data
Underlying data on the estimated incidence of dengue hos-
pitalisations in the trials is available from Shridar et al.13 and 
digitalised in the analysis script at https://github.com/ 
StefanFlasche/Denvaxia-in-Phillippines
Extended data
Scripts used for analysis available from: https://github.com/ 
StefanFlasche/Denvaxia-in-Phillippines
Archived scripts as at time of publication: http://doi.org/ 
10.5281/zenodo.349682023
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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While Dengvaxia, the first licensed dengue vaccine, is shown to illicit effective protection in individuals
pre-exposed with dengue, increased risks of hospitalization in seronegative individuals were
demonstrated in retrospective analyses. This has resulted in the suspension of the vaccination program in
the Philippines. The WHO has altered its recommendation on the use of Dengvaxia. Use should be
restricted to highly endemic areas (seroprevalence >70%), exclude the youngest age groups, and
pre-vaccination screening should be incorporated into the strategy.
The mixed outcomes of the vaccine have raised questions on its population-level impact. In this paper,
the authors extrapolate estimates from the Phase-3 dengvaxia trial to estimate, among observed
vaccinated severe cases/ hospitalizations, what proportion is attributable to vaccine failure vs vaccine
induced morbidity. In addition, they estimated the number of cases averted per vaccine induced case.
They conclude that, in a setting with high enough seroprevalence, the number of averted cases would
outnumber the number of cases attributable to excess risk of enhanced disease in seronegative vaccines.
The work is timely and well performed and limitations are adequately described. I do have a few
comments, in particular about the description of the methods and presentation of results.
Methods
The methods are quite densely described and become more clear once referring to the
(well-documented!) code. The paper would benefit from a more detail in the methods, including the
relevant equations.
 
Further, from the methods itself it is not clear how the authors derive the time-dependent estimates
as shown in figure 1.
Results
Figure 1 is nice, but does not show the full picture given that the incidence increases over time.
Therefore, the larger proportion of cases attributable to the vaccine in seronegative cases towards
the end of the follow-up contributes more to the overall number of cases. A cumulative proportion
might be more informative.
 
It is not always clear what is meant with seroprevalence. If this refers to the seroprevalence in the
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 It is not always clear what is meant with seroprevalence. If this refers to the seroprevalence in the
population rather than the 9-16 year-olds, the seroprevalence in the code should be adjusted to
reflect the seroprevalence expected in that age-group.  
 
The authors report on the sensitivity of their results for settings with higher and low seroprevalence.
This is a big uncertainty and a hurdle for implementation. Particularly since local, age-specific
seroprevalence is hard to obtain. It would therefore be informative to see a bit larger sweep across
seroprevalences, particularly for the number of hospitalized cases averted per vaccine-induced
case and how this varies across endemicities. 
 
Lastly, a small textual remark: it is not clear to me why only vaccine failure in seropositives is
considered a breakthrough infection.
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In the aftermath of the Philippines dengue vaccine controversy, the authors contribute an analysis of the
expected dengue hospitalizations and severe illnesses among the approximately 800,000 9-10 year-old
school children who participated in a vaccination program with the newly licensed vaccine during 2016
and 2017 in highly dengue endemic areas of the Philippines.
In November 2017 Sanofi Pasteur reported that dengue seronegative children of all ages vaccinated with
CYD-TDV (Dengvaxia) had higher risk of hospitalization (1.75, 1.14-2.70, reference 13)) and severe
dengue illness, while the vaccine considerably reduced such risk in seropositive children (0.32,
0.23-0.45). This announcement at the time of government turnover precipitated the Philippines
controversy and an end to the program. The new data resulted in updated WHO Strategic Advisory Group
of Experts (SAGE) recommendations for CYD-TDV emphasizing a preferred approach of pre-vaccination
screening for prior dengue infection before vaccination.
The authors, all members of the WHO SAGE committee making recommendations on CYD-TDV,
estimate the proportions of hospitalized and severe cases among vaccinated Philippine children using the
Sanofi Phase 3 trial data for children 9 years and older. The calculations make use of published
virologically confirmed hospitalization incidence and hazard ratios in seropositive and seronegatives
including supplemental data from the clinical trials over five years post vaccination series completion, and
an empirically realistic assumption of 85% seroprevalence in the 9-10 year olds in the Philippine sites.
The results clarify that the majority of hospitalizations and severe illnesses in vaccinated children are likely
due to CYD-TDV vaccine breakthrough in seropositive children, while excess cases associated in
vaccinated seronegative children would comprise about a quarter of all such cases. Another 25 percent of
hospitalizations and severe illnesses would have occurred in seronegative children regardless of
vaccination. With the seroprevalence assumption of 85%, the vaccination program would avert 18
hospitalizations for each excess hospitalization in seronegative vaccinees. Using the same proportions as
severe cases, the authors also estimate that 10 deaths would be prevented for each death that might
have occurred in vaccinated seronegatives.
The methods calculations are standard epidemiologic measures (i.e., excess risk, population attributable
fractions, and cases averted), and data and code for the generating the estimates are conveniently placed
in a github link for accessibility. The discussion appropriately includes a sensitivity analysis using
seroprevalences of 70% and 90% since dengue seroprevalence has a significant effect on the estimates.
However, some aspects of the methods could be expanded to improve reader accessibility.
The manuscript is well written and provides a useful perspective on the difficult Philippines situation. The
figure is quite helpful in conveying the proportion and timing of all hospitalized cases attributable to
vaccinating seronegatives. The authors clearly state the background for the study and the limitations of
the analysis, including that this analysis cannot address individual causality for severe illness. The
manuscript concludes with an appropriate summary of the need for public health decision makers to
balance the potential population benefits of CYD-TDV with challenges of logistics and specificity of
pre-vaccination screening, and communications to the public and medical communities of the relative
benefits and risk.
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Page 10 of 12
Wellcome Open Research 2019, 4:165 Last updated: 26 NOV 2019
 Comments
Introduction
Given the reference to vaccine breakthrough in the methods and results, providing summary
estimates of CYD-TDV vaccine efficacy would be helpful to the reader.
Methods
Little numerical data are provided in the methods. A table or figure of the trial populations would be
helpful.
 
While the code with the formulas and calculations is on the github, providing the formulas for the
cases averted and excess cases in the text would be useful to understand the estimates.
Results
That the R code on the Github makes calculations with 70% seroprevalence when the paper
presents results based on the assumed 85% seroprevalence is somewhat confusing.
Discussion
Page 6, first paragraph: The authors indicate they did not provide confidence intervals for the point
estimates of hospitalizations and severe illnesses, which as stated have substantial uncertainty,
because of incertain uncertainty arising from likely correlation of trial incidence and relative risk
confidence intervals. As the first author has published on mathematical models of the Sanofi trial
(PLoS Med. 2016 ), it seems reasonable that the paper could provide confidence intervals for the
point estimates.
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